# Moderna

mRNA medicine pioneer — Spikevax COVID vaccine and expanding pipeline in flu, RSV, and cancer; proprietary LNP delivery and GMP mRNA manufacturing in Norwood, MA.

Source: https://en.bioecon.ru/companies/moderna/
Updated: 2026-06-19

- Country: United States
- Revenue: $3.2B
- Employees: ~5,000 emp

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | $2.6 billion raised via convertible notes offering in 2026 | https://www.biopharmadive.com/news/fda-covid-vaccines-moderna-generate-profound-bixlenvo/828929/ |
| Revenue | $1.9 billion in 2025 | https://www.nasdaq.com/press-release/moderna-reports-fourth-quarter-and-fiscal-year-2025-financial-results-and-provides, https://www.stocktitan.net/sec-filings/MRNA/10-k-moderna-inc-files-annual-report-aebfa7a63ded.html |
| Revenue | $145 million in Q2 2026 | https://last10k.com/sec-filings/mrna/0001682852-26-000150.htm, https://www.sec.gov/Archives/edgar/data/1682852/000168285226000147/exhibit9912026q2pressrelea.htm |
| Production site | Norwood, Massachusetts (Moderna Technology Center); Marlborough, Massachusetts; facilities in the UK, Canada, and Australia | https://www.modernatx.com/en-US/about-us/our-story, https://www.nasdaq.com/press-release/moderna-reports-fourth-quarter-and-fiscal-year-2025-financial-results-and-provides, https://www.stocktitan.net/sec-filings/MRNA/10-k-moderna-inc-files-annual-report-aebfa7a63ded.html |
| Headcount | 4,700 employees as of end of fiscal year 2025 | https://financhle.com/company/MRNA/employees, https://tickerleague.com/companies/MRNA/employee-count |
| Regulatory approval | Spikevax (COVID-19), mNEXSPIKE (COVID-19), mRESVIA (RSV), and mCOMBRIAX (Flu+COVID combo, EU approved) | https://www.biospace.com/press-releases/moderna-receives-u-s-fda-approval-for-updated-2026-2027-covid-19-vaccines, https://www.fda.gov/vaccines-blood-biologics/spikevax, https://www.modernatx.com/en-US/about-us/our-story, https://www.stocktitan.net/sec-filings/MRNA/10-k-moderna-inc-files-annual-report-aebfa7a63ded.html |

Independent sources: biopharmadive.com, biospace.com, fda.gov, financhle.com, last10k.com, nasdaq.com, sec.gov, stocktitan.net, tickerleague.com

## Technologies

- [Drug & vaccine development](https://en.bioecon.ru/technology/drug-vaccine-development/)
- [mRNA platforms & LNP delivery](https://en.bioecon.ru/technology/mrna-platforms-lnp-delivery/)